Literature DB >> 23707162

Transcutaneous immunization of healthy volunteers with an attenuated Listeria monocytogenes vaccine strain and cholera toxin adjuvant.

Elizabeth H Eypper1, Paul V Johnson, Eva I Purro, Elizabeth L Hohmann.   

Abstract

BACKGROUND: Attenuated Listeria monocytogenes vaccine strains have been administered intravenously (Le et al., Maciag et al.) and orally (Angelakopoulos et al., Johnson et al.) to humans. Here, one was given transcutaneously with cholera toxin adjuvant.
METHODS: Eight healthy volunteers were studied (5 active, 3 placebo). Safety was assessed by physical exam and labs. Systemic immunological responses were measured by ELISA and IFN-gamma ELISpot.
RESULTS: 4/5 active volunteers had cellular responses to listerial antigens. 5/5 active volunteers showed humoral responses to cholera toxin.
CONCLUSIONS: An attenuated L. monocytogenes vector was safely administered transcutaneously. Topical administration appeared at least as immunogenic as previously studied oral delivery.
Copyright © 2013 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23707162      PMCID: PMC3831363          DOI: 10.1016/j.vaccine.2013.05.028

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  11 in total

1.  A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction.

Authors:  Dung T Le; Dirk G Brockstedt; Ran Nir-Paz; Johannes Hampl; Shruti Mathur; John Nemunaitis; Daniel H Sterman; Raffit Hassan; Eric Lutz; Bentley Moyer; Martin Giedlin; Jana-Lynn Louis; Elizabeth A Sugar; Alice Pons; Andrea L Cox; Jordana Levine; Aimee Luck Murphy; Peter Illei; Thomas W Dubensky; Joseph E Eiden; Elizabeth M Jaffee; Daniel A Laheru
Journal:  Clin Cancer Res       Date:  2011-12-06       Impact factor: 12.531

Review 2.  Intradermal fractional dose inactivated polio vaccine: a review of the literature.

Authors:  Katherine S Nelson; Julia M Janssen; Stephanie B Troy; Yvonne Maldonado
Journal:  Vaccine       Date:  2011-11-17       Impact factor: 3.641

3.  Primary cutaneous listeriosis in adults: an occupational disease of veterinarians and farmers.

Authors:  J McLauchlin; J C Low
Journal:  Vet Rec       Date:  1994 Dec 24-31       Impact factor: 2.695

4.  Attenuated Listeria monocytogenes vaccine vectors expressing influenza A nucleoprotein: preclinical evaluation and oral inoculation of volunteers.

Authors:  Paul V Johnson; Barbra M Blair; Skye Zeller; Camille N Kotton; Elizabeth L Hohmann
Journal:  Microbiol Immunol       Date:  2011-05       Impact factor: 1.955

5.  The first clinical use of a live-attenuated Listeria monocytogenes vaccine: a Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix.

Authors:  Paulo Cesar Maciag; Sinisa Radulovic; John Rothman
Journal:  Vaccine       Date:  2009-05-03       Impact factor: 3.641

Review 6.  Skin-resident T cells: the ups and downs of on site immunity.

Authors:  Rachael A Clark
Journal:  J Invest Dermatol       Date:  2009-08-13       Impact factor: 8.551

7.  Safety and shedding of an attenuated strain of Listeria monocytogenes with a deletion of actA/plcB in adult volunteers: a dose escalation study of oral inoculation.

Authors:  Haroula Angelakopoulos; Katharina Loock; David M Sisul; Eric R Jensen; Jeff F Miller; Elizabeth L Hohmann
Journal:  Infect Immun       Date:  2002-07       Impact factor: 3.441

8.  Improved immune responses to influenza vaccination in the elderly using an immunostimulant patch.

Authors:  Sarah A Frech; Richard T Kenney; Christian A Spyr; Hedvika Lazar; Jean-François Viret; Christian Herzog; Reinhard Glück; Gregory M Glenn
Journal:  Vaccine       Date:  2005-01-04       Impact factor: 3.641

9.  Skin infection generates non-migratory memory CD8+ T(RM) cells providing global skin immunity.

Authors:  Xiaodong Jiang; Rachael A Clark; Luzheng Liu; Amy J Wagers; Robert C Fuhlbrigge; Thomas S Kupper
Journal:  Nature       Date:  2012-02-29       Impact factor: 49.962

10.  Safety and immunogenicity of a prototype enterotoxigenic Escherichia coli vaccine administered transcutaneously.

Authors:  Fernando Güereña-Burgueño; Eric R Hall; David N Taylor; Frederick J Cassels; Daniel A Scott; Marcia K Wolf; Zachary J Roberts; Galina V Nesterova; Carl R Alving; Gregory M Glenn
Journal:  Infect Immun       Date:  2002-04       Impact factor: 3.441

View more
  5 in total

Review 1.  Enhancing vaccine effectiveness with delivery technology.

Authors:  Marie Beitelshees; Yi Li; Blaine A Pfeifer
Journal:  Curr Opin Biotechnol       Date:  2016-03-06       Impact factor: 9.740

2.  Determination of Depth-Dependent Intradermal Immunogenicity of Adjuvanted Inactivated Polio Vaccine Delivered by Microinjections via Hollow Microneedles.

Authors:  Pim Schipper; Koen van der Maaden; Stefan Romeijn; Cees Oomens; Gideon Kersten; Wim Jiskoot; Joke Bouwstra
Journal:  Pharm Res       Date:  2016-06-17       Impact factor: 4.200

3.  Immunogenicity of a West Nile virus DIII-cholera toxin A2/B chimera after intranasal delivery.

Authors:  Juliette K Tinker; Jie Yan; Reece J Knippel; Panos Panayiotou; Kenneth A Cornell
Journal:  Toxins (Basel)       Date:  2014-04-22       Impact factor: 4.546

Review 4.  Intracellular delivery of biologic therapeutics by bacterial secretion systems.

Authors:  Barnabas James Walker; Guy-Bart V Stan; Karen Marie Polizzi
Journal:  Expert Rev Mol Med       Date:  2017-04-06       Impact factor: 5.600

Review 5.  Live-Attenuated Bacterial Vectors: Tools for Vaccine and Therapeutic Agent Delivery.

Authors:  Ivan Y C Lin; Thi Thu Hao Van; Peter M Smooker
Journal:  Vaccines (Basel)       Date:  2015-11-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.